Eagle Pharma rises after FDA approves generic to Endo's Vasostrict

Eagle Pharmaceuticals

15/12/2021 19:31

** Drugmaker Eagle Pharmaceuticals Inc's  EGRS.O  shares
rise 8.9% to $50.83 
    ** Co says U.S. FDA has approved co's generic version of
Endo International PLC's  ENDP.O  Vasostrict, used to treat
shock in patients whose blood vessels suddenly relax
 urn:newsml:reuters.com:*:nL4N2T03XK
    ** ENDP shares down 6.4% at $4
    ** In August, a Delaware federal court had ruled that
Eagle's proposed generic of the drug did not infringe Endo's
patents
    ** EGRX says it anticipates a 180-day marketing exclusivity
    ** Including session gains, EGRX stock had risen 9% YTD 

 (Reporting by Manas Mishra)
 ((Manas.Mishra@thomsonreuters.com;
www.twitter.com/Manasmishra24))